RO7121661 is a bispecific antibody that targets two proteins, PD1 and TIM3. It is designed to help the immune system recognize and attack cancer cells more effectively. This medication is being tested to see if it can improve outcomes for patients with advanced or metastatic squamous cell carcinoma of the esophagus.

RO7247669 is another bispecific antibody that targets PD1 and LAG3. Like RO7121661, it aims to enhance the immune system’s ability to fight cancer by blocking these proteins, which can help the body better identify and destroy cancer cells. This study is evaluating its effectiveness in improving survival rates for patients with this type of esophageal cancer.

Nivolumab is a medication that works by blocking the PD1 protein on immune cells. This action helps the immune system to detect and attack cancer cells. It is already used in various cancer treatments and is being used in this trial as a comparison to the new investigational drugs.

Squamous Cell Carcinoma of the Esophagus – This is a type of cancer that begins in the flat cells lining the esophagus, the tube that carries food from the throat to the stomach. It is characterized by the abnormal growth of these squamous cells, which can form a tumor. As the disease progresses, the tumor may grow and invade deeper layers of the esophagus and potentially spread to nearby tissues or other parts of the body. Symptoms often include difficulty swallowing, weight loss, and chest pain. The disease is more common in certain regions and populations, often linked to lifestyle factors such as smoking and alcohol consumption. Early detection can be challenging, as symptoms may not appear until the disease is advanced.